Search

Purpose: The relationship between serum albumin levels and severe limitations in ADLs among stroke patients remains unclear. Specifically, the dose–response relationship between the two needs further exploration. This study aims to provide further results. Materials and methods: This study examined cross-sectional data from patients aged 18 years or older with a diagnosis of stroke confirmed by cranial CT or MRI within 24 h of admission, gathered from January 2020 to August 2022. Data included serum albumin levels, Barthel Index scores recorded after admission, and other essential variables. Results: The study comprised 2,393 stroke patients. After adjusting for confounding factors, the multivariate analysis revealed a 7% decrease in severe impairment of ADL after stroke for every unit (g/L) increase in serum albumin levels. Compared with individuals with lower serum albumin levels (Q1: ≤ 37.4 g/L), the adjusted odds ratios (OR) for severe of ADL impairment among stroke patients in Q2 (37.4–40.21 g/L), Q3 (40.21–42.80 g/L), and Q4 (≥42.8 g/L) were 0.68 (95% CI: 0.4–1.15, p = 0.148), 0.55 (95% CI: 0.32–0.97, p = 0.04), and 0.64 (95% CI: 0.37–1.15, p = 0.139), respectively. The relationship between serum albumin and severe impairment of ADLs in stroke patients showed an L-shaped curve (non-linear, p = 0.002), with an inflection point at 38.0 g/L. The OR for significant impairment of ADLs was 0.680 (95% CI: 0.568–0.814, p < 0.001) in participants with serum albumin levels <38.0 g/L. However, when serum albumin levels were greater than or equal to 38.0 g/L, the severe impairment of ADLs no longer decreased with rising serum albumin levels. Conclusion: In summary, an L-shaped connection with an approximate inflection point of 38.0 g/L was found between blood albumin levels and significant ADL impairment in stroke patients. The results of this study suggest that increasing serum albumin levels can significantly help improve the severity of ADL impairment in stroke patients, particularly those with serum albumin levels below 38.0 g/L. [ABSTRACT FROM AUTHOR]

BACKGROUND: In the healthy body, the fascial system maintains elasticity and coordination of movements. If these functions are destroyed, facial paraly appears. Myofascial induction therapy (MIT), a manual physical therapy method that focuses on restoring altered fascial tissue, is prevalently and widely used in clinical treatment. OBJECTIVE: The study aimed to observe the application of MIT in the rehabilitation of patients with acute facial palsy. METHODS: Sixty-eight patients with acute facial palsy were divided into control group and manual treatment group. The control group received drug treatments, such as prednisone, methylcobalamin, and vitamin B1, and instrumental physical therapy, such as semiconductor laser, shortwave therapy, and facial muscle training. In addition to these treatments, the manual treatment group received MIT. Both groups were treated for 4 weeks. The patients were assessed using the following methods: the House-Brackmann facial nerve function evaluation, Sunnybrook facial grading system, facial nerve electrophysiological examination compound muscle action potential (CMAP) amplitude, and blink reflex (BR) R1 latency. RESULTS: House-Brackmann and Sunnybrook scores and CMAP amplitude and BRR1 latencies were significantly different between the two groups (p < 0.05). Furthermore, the manual treatment group showed greater improvement than the control group (p < 0.05). CONCLUSIONS: Treatment with MIT promoted better recovery of acute facial palsy and thus may be considered a valid rehabilitation intervention that is worthy of clinical application. [ABSTRACT FROM AUTHOR]